MedTrace Logo

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

NCT04582552 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-01-20

No results posted yet for this study

Summary

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment. The available evidence suggests that BRCAmt or HRD-positive is an effective biological marker for PARPi. However, in our previous clinical observation, it was found that the tumor burden may be the potential clinical markers PARPi. We intend to develop a real-world study to confirm the potential clinical markers and explore new clinical markers for PARPi.

Conditions

Interventions

DRUG

PARP inhibitors

Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.

Sponsors & Collaborators

  • Xiaoxiang Chen

    lead OTHER

Principal Investigators

  • Xiaoxiang Chen, MD,PhD · Jiangsu Cancer Institute & Hospital

  • Jing Ni, MD · Jiangsu Cancer Institute & Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2022-05-31
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04582552 on ClinicalTrials.gov